Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care.
Breast Cancer Res Treat
; 206(2): 227-244, 2024 Jul.
Article
en En
| MEDLINE
| ID: mdl-38676808
ABSTRACT
PURPOSE:
Neoadjuvant chemotherapy (NAC) for triple-negative (TN) and Her2-positive (HER2) breast cancers is supported by international guidelines as it can decrease extent of surgery, provide prognostic information, and allow response-driven adjuvant therapies. Our goal was to describe practice patterns for patients with TN and HER2-positive breast cancer and identify the factors associated with the receipt of NAC versus surgery as initial treatment.METHODS:
A retrospective population-based cohort study of adult women diagnosed with stage I-III TN or HER2-positive breast cancer (2012-2020) in Ontario was completed using linked administrative datasets. The primary outcome was NAC as first treatment. The association between NAC and patient, tumor, and practice-related factors was examined using multivariable logistic regression models.RESULTS:
Of 14,653 patients included, 23.9% (n = 3500) underwent NAC as first treatment. Patients who underwent NAC were more likely to be younger and have larger tumors, node-positive disease, and stage 3 disease. Of patients who underwent surgery first, 8.8% were seen by a medical oncologist prior to surgery. On multivariable analysis, increasing tumor size (T2 vs T1/T0 2.75 (2.31-3.28)) and node-positive (N1 vs N0 OR 3.54 (2.92-4.30)) disease were both associated increased odds of receiving NAC.CONCLUSION:
A considerable proportion of patients with TN and HER2-positive breast cancer do not receive NAC as first treatment. Of those, most were not assessed by both a surgeon and medical oncologist prior to initiating therapy. This points toward potential gaps in multidisciplinary assessment and disparities in receipt of guideline-concordant care.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Receptor ErbB-2
/
Terapia Neoadyuvante
/
Neoplasias de la Mama Triple Negativas
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Breast Cancer Res Treat
Año:
2024
Tipo del documento:
Article